Results of the Jordan medicine price and availability survey conducted in 2004.

Slides:



Advertisements
Similar presentations
Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
Advertisements

AGVISE Laboratories %Zone or Grid Samples – Northwood laboratory
Introduction of the Annual Report 1. Workshop towards equitable and affordable medicine prices policy in Jordan Dead Sea, Jordan Dead Sea, Jordan 4–5.
Medicine Prices Matter to People and Insurance Companies Margaret Ewen Health Action International.
Direct costs and availability of diabetes medicines in low-income and middle-income countries Birgit Volman 27/08/2008 Meeting on Access to Medicines for.
1 Paying the Price Margaret Ewen Health Action International Europe.
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
1 Medicines for Chronic Diseases: too costly, too scarce, too important to ignore Margaret Ewen Health Action International.
Completing the Medicine Price Data Collection form Presentation template for adaptation and use in medicine prices and availability survey training workshop.
MEDICINES PRICES IN INDONESIA Ms. Selma Siahaan Center for Health Services and Technology R&D National Institute of Health R&D Indonesia 14 June 2006.
1 Medicine Availability, Prices and Affordability in West Bengal, India (2004) DALIA DEY CUTS & CDMU.
1 Medicine Prices, Availability and Affordability Margaret Ewen Health Action International.
Lebanon, 2004 Medicine price survey in Lebanon, 2004 undertaken by Dr Rita Karam, Ministry of Health Marg Ewen (on behalf of Dr Karam) WHO/HAI post-medicine.
Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.
Syria,2004 Medicine price survey in Syria, 2004 undertaken by Pharmaceutical Studies Directorate, Ministry of Health Presentation by Razan Sallouta WHO/HAI.
A MEDICINE PRICES SURVEY IN CHINA Presentation by Dr Xiaoxia Hu Research by Dr Sun Qiang and Dr Xiaoxia Hu June, 2006.
1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.
Mohamed Izham Mohamed Ibrahim
August 27th Availability, Pricing and Affordability of Cardiovascular Medicines Draft report for comments Maaike S.M. van Mourik University.
The prices of medicines worldwide & how they are determined Margaret Ewen Health Action International Europe Co-ordinator WHO/HAI Project on Medicine Prices.
Measuring Medicine Prices and Availability – a new Methodology and few Indian Survey Results Dr. Anita Kotwani Department of Pharmacology Vallabhbhai Patel.
MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Price, availability and affordability of medicines international comparison of 29 surveys Presented by: Richard Laing World Health Organization, Geneva.
Medicine prices, availability, affordability and component prices Margaret Ewen Health Action International, The Netherlands Coordinator WHO/HAI Project.
Medicine Prices and Affordability Survey in West Bengal, India ( )
David Burdett May 11, 2004 Package Binding for WS CDL.
Create an Application Title 1Y - Youth Chapter 5.
CALENDAR.
1 Screening & Eligibility Jeopardy Title V/PHC.
2.11.
The 5S numbers game..
Break Time Remaining 10:00.
The basics for simulations
A sample problem. The cash in bank account for J. B. Lindsay Co. at May 31 of the current year indicated a balance of $14, after both the cash receipts.
MCQ Chapter 07.
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
TCCI Barometer March “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
Copyright © 2012, Elsevier Inc. All rights Reserved. 1 Chapter 7 Modeling Structure with Blocks.
Medicine prices: a WHO/Health Action International collaboration The approach, some results, and implications for policy to improve the affordability of.
Adding Up In Chunks.
MaK_Full ahead loaded 1 Alarm Page Directory (F11)
TCCI Barometer September “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
THE COMMONWEALTH FUND Figure 1. Three of Five Health Care Opinion Leaders Feel that Mixed Private-Public Group Insurance Is an Effective Approach to Achieving.
2011 WINNISQUAM COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=1021.
Before Between After.
2011 FRANKLIN COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=332.
Subtraction: Adding UP
1 Non Deterministic Automata. 2 Alphabet = Nondeterministic Finite Accepter (NFA)
Static Equilibrium; Elasticity and Fracture
Converting a Fraction to %
Clock will move after 1 minute
Select a time to count down from the clock above
1 Non Deterministic Automata. 2 Alphabet = Nondeterministic Finite Accepter (NFA)
Schutzvermerk nach DIN 34 beachten 05/04/15 Seite 1 Training EPAM and CANopen Basic Solution: Password * * Level 1 Level 2 * Level 3 Password2 IP-Adr.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 3 rd 2010 Alexandra Cameron, Department of Essential Medicines.
1 Generating reliable evidence: measuring medicine prices and availability Dr Richard Laing Department of Essential Medicines and Pharmaceutical Policy.
Paying the Price: The Affordability of Medicines Across the Commonwealth (and elsewhere) Margaret Ewen Health Action International.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 18 th 2009 Alexandra Cameron, Department of Essential Medicines.
EXPERIENCES IN SOUTH AFRICA WITH THE INTRODUCTION OF PHARMACEUTICAL PRICING LEGISLATION Zokufa HZ, Pillay T Pharmaceutical Policy and Planning, Department.
DOES REGISTRATION OF SEVERAL GENERICS TRANSLATE INTO MORE AND CHEAPER DRUGS FOR THE PATIENTS’ IN SRI LANKA? Fernandopulle BMR Senarathna SMDKG Department.
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1,Andrews Annan E. 2, Koduah A. 1,
Medicines prices: measurement and findings in countries Richard Laing PSM - WHO Gilles Forte TCM - WHO Margaret Ewen HAI - Europe.
The Pharmaceutical Situational Analysis in Mongolia 1 Chimedtseren Munkhdelger 1 Sanjjav Tsetsegmaa 2, 1 Ministry of Health, 2 Pharmacy School, Health.
Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Out-of-pocket and Out-of-reach Margaret Ewen, Coordinator, Global Projects (Pricing) Health Action International Amsterdam.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, 2012 Richard Laing with materials provided by Alexandra Cameron, Department.
Medicine prices and availability, evidence for policy
Presentation transcript:

Results of the Jordan medicine price and availability survey conducted in 2004

Presentation - Methodology - Results - Recommendations - Activities since 2004

Methodology medicine prices, availability Measured medicine prices, availability and affordability and affordability using the standardized WHO/HAI methodology Data collected: Public sector procurement prices Public sector patient prices & availability Private sector patient prices & availability Medicine types surveyed: Originator brand (identified centrally) Most sold generic equivalent (identified centrally) Lowest priced generic equivalent (at each outlet) Price components: hypothetical - not measured in the field

Jordan Amman Middle 1 2 tertiary hospitals 2 district hospitals 1 PHC 5 private pharmacies Zarqa Middle 2 2 tertiary hospitals 3 PHC 5 private pharmacies Irbid North 1 tertiary hospital 1 district hospital 3 PHC 5 Private pharmacies Karak South 1 tertiary hospital 1 district hospital 1 PHC 5 Private pharmaciesSampling Overall sampling: 18 public sector outlets, 20 private retail pharmacies Public sector procurement data from Ministry of Health

Medicines surveyed WHO/HAI core list medicines - 23 aciclovir 200mg, amitriptyline 25mg, amoxicillin 250mg beclometasone 0.05mg/dose inhaler, captopril 25mg carbamazepine 200mg, ceftriaxone 1g inj, ciprofloxacin 500mg co-trimoxazole paed susp, diazepam 5mg, diclofenac 25mg fluoxetine 20mg, fluphenazine 25mg/ml inj, glibenclamide 5mg hydrochlorothiazide 25mg, losartan 50mg, metformin 500mg nifedipine retard 20mg, omeprazole 20mg, phenytoin 100mg ranitidine 150mg, salbutamol 0.1mg/dose inhaler Supplementary medicines - 6 diltiazem 60mg, enalapril 20mg, fluconazole 150mg furosemide 40mg, methyldopa 250mg, simvastatin 20mg

Data quality assurance Training workshop for data collectors (pharmacists from Inspection Dept) Data collection forms checked in the field & 10% verified Pre-programmed MS Excel workbook provided with WHO/HAI manual Data entry checked using 'double entry' function Workbooks 'data checker' function used Automated data analysis Data reviewed by WHO/HAI

Data analysis Affordability Assessed by comparing the cost of medicine treatment, using standard dosing regimens, to the daily wage of the lowest paid unskilled government worker - 3 Jordan Dinar ($ 4.22) / day at time of survey Acute condition - a weeks course of treatment Chronic condition - 30 days supplyAvailability Calculated as the percentage (%) of outlets stocking the product on the day of data collection

Prices Calculated as Median Price Ratio (MPR) - local price compared to an international reference price (converted to JD) Management Sciences for Healths International Drug Price Indicator Guide 2003 used as reference: median prices of high quality generics offered to developing countries in bulk by different suppliers MPR 0.5 means that the local medicine price is half the international reference price MPR 2 means that the local medicine price is twice the international reference price MPR only calculated if medicine found in 4 or more outlets

Availability - public sector Availability - public sector Median availability (29 meds) (29 meds) Originator Brand Lowest priced generic 0%27.8%

Availability - private sector Availability - private sector Median availability (29 meds) 0riginator Brand Lowest priced generic 60%80%

Prices - public sector Government procurement prices Public sector patient prices OB LPG LPGOB Median MPR (1) Ciprofloxacin Co-trimoxazole Diazepam Amitriptyline3.42 Phenytoin Furosemide medicines: little difference between procurement price & patient price in the public sector

Patient prices - private retail pharmacies Originator brand Lowest priced Lowest pricedgeneric Median MPR Salbutamol Metformin Amoxicillin Captopril Hydrochlorothiazide49.5 Ciprofloxacin LPGs: private sector prices were over 10 times public sector prices LPGs: private sector prices were over 10 times public sector prices

Examples of medicines with very high prices in private retail pharmacies originator brands and lowest priced generics

Affordability (No. of days wages) Daily wage 3 JD PublicPrivate = US $ 4.22 /day OB LPG LPGOBLPG Ranitidine, peptic ulcer 150mg twice daily x 30 days Diclofenac, arthritis 25mg twice daily x 30 days Beclometsone 0.05mg/dose inhaler x Fluoxetine, depression 20mg twice daily x 30 days

Price components – hypothetical case Amoxil (amoxicillin) 250 mg, 20 tab, Private Sector, Imported Type of charge Amount of charge Price of dispensed quantity Cumulative % mark-up Cost & Freight 4.040% Insurance 1 % 4.081% Bank fees 1 % % Transport & clearance 1.5 % % Import fees 0 % % Added fees 0.2 % % Wholesale mark-up 19 % % Pharmacy mark-up 26 % % VAT4% % some medicines, excluding antibiotics, are charged up to 5% import fee depending on country & trade agreements, resulting in a cumulative mark- up of up to 70%

Summary of findings Prices Public procurement prices were acceptable for generics but some higher priced originator brands are being purchased Public sector patient prices were similar to procurement prices Private sector patient prices were extremely high for both originator brands and lowest priced genericsAvailability very poor in the public sector, much better in the private sector

Summary of findings Affordability Treatments generally affordable in the public sector but as availability very poor, most people have to purchase medicines from private pharmacies where treatments are less affordable. Private sector – originator brands not affordable (acute & chronic conditions). Lowest priced generics affordable for some acute conditions but few chronic conditions. Price components cumulative mark-ups thought to be import fee charged for most medicines, VAT charged

Recommendations Review the current pricing policy to ascertain reasons for high medicine prices especially in the private sector but also some high procurement prices Initiate international tenders and only purchase originator brands where no reasonable alternative or price offered is lowest Investigate reasons for low availability in the public sector. Supply and demand should be regularly monitored to ensure accurate financing mechanisms to improve funding of essential medicines. Extend the NHI Scheme to cover the whole population with the aim of lower prices (greater volume; stronger negotiation power for the government) and increased availability

Recommendations Investigate prescribing and dispensing practices, legalise and encourage generic substitution and educate health professionals and consumers on acceptability of low priced generics Provide incentives for the dispensing of low priced generics Abolish taxes on medicines Regularly monitor prices, availability and affordability & publish results to health professionals and consumers Conduct a price components field study

Activities since 2004 New pricing policy developed in January 2004 (prior to survey) and implemented New pricing policy developed in January 2004 (prior to survey) and implemented Some amendments introduced in May 2007 Some amendments introduced in May 2007